Inflammation in Acute CNS Injury: a Focus on the Role of Substance P

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2015 Apr 2

PMID 25827155

Citations 33

Authors

F Corrigan

R Vink

R J Turner

Affiliations

Soon will be listed here.

Abstract

Recently, a number of reports have shown that neurogenic inflammation may play a role in the secondary injury response following acute injury to the CNS, including traumatic brain injury (TBI) and stroke. In particular substance P (SP) release appears to be critically involved. Specifically, the expression of the neuropeptide SP is increased in acute CNS injury, with the magnitude of SP release being related to both the frequency and magnitude of the insult. SP release is associated with an increase in blood-brain barrier permeability and the development of vasogenic oedema as well as neuronal injury and worse functional outcome. Moreover, inhibiting the actions of SP through use of a NK1 receptor antagonist is highly beneficial in both focal and diffuse models of TBI, as well as in ischaemic stroke, with a therapeutic window of up to 12 h. We propose that NK1 receptor antagonists represent a novel therapeutic option for treatment of neurogenic inflammation following acute CNS injury.

Citing Articles

NK1 tachykinin receptor antagonist treatment reduces cerebral edema and intracranial pressure in an ovine model of ischemic stroke.

Sorby-Adams A, Marian O, Bilecki I, Elms L, Yassi N, Hood R J Cereb Blood Flow Metab. 2024; 44(10):1759-1773.

PMID: 38546535 PMC: 11494854. DOI: 10.1177/0271678X241241907.

Post-treatment with maropitant reduces oxidative stress, endoplasmic reticulum stress and neuroinflammation on peripheral nerve injury in rats.

Niella R, Correa J, Dos Santos J, Lima L, da Costa Marques C, Santos L PLoS One. 2024; 19(3):e0287390.

PMID: 38507417 PMC: 10954158. DOI: 10.1371/journal.pone.0287390.

Effects of a neurokinin-1 receptor antagonist in the acute phase after thoracic spinal cord injury in a rat model.

Zheng G, Harms A, Tail M, Zhang H, Nimmo A, Skutella T Front Mol Neurosci. 2023; 16:1128545.

PMID: 37251648 PMC: 10213275. DOI: 10.3389/fnmol.2023.1128545.

A Potential Role for Substance P in West Nile Virus Neuropathogenesis.

Ronca S, Gunter S, Kairis R, Lino A, Romero J, Pautler R Viruses. 2022; 14(9).

PMID: 36146768 PMC: 9503494. DOI: 10.3390/v14091961.

Neurokinin receptors and their implications in various autoimmune diseases.

Mishra A, Lal G Curr Res Immunol. 2022; 2:66-78.

PMID: 35492389 PMC: 9040085. DOI: 10.1016/j.crimmu.2021.06.001.

References

Penny G, Afsharpour S, Kitai S . The glutamate decarboxylase-, leucine enkephalin-, methionine enkephalin- and substance P-immunoreactive neurons in the neostriatum of the rat and cat: evidence for partial population overlap. Neuroscience. 1986; 17(4):1011-45. DOI: 10.1016/0306-4522(86)90076-x. View

Ebner K, Singewald N . The role of substance P in stress and anxiety responses. Amino Acids. 2006; 31(3):251-72. DOI: 10.1007/s00726-006-0335-9. View

Carthew H, Ziebell J, Vink R . Substance P-induced changes in cell genesis following diffuse traumatic brain injury. Neuroscience. 2012; 214:78-83. DOI: 10.1016/j.neuroscience.2012.04.028. View

Severini C, Improta G, Salvadori S, Erspamer V . The tachykinin peptide family. Pharmacol Rev. 2002; 54(2):285-322. DOI: 10.1124/pr.54.2.285. View

Smith D, Meaney D, Shull W . Diffuse axonal injury in head trauma. J Head Trauma Rehabil. 2005; 18(4):307-16. DOI: 10.1097/00001199-200307000-00003. View

Morganti-Kossmann M, Rancan M, Stahel P, Kossmann T . Inflammatory response in acute traumatic brain injury: a double-edged sword. Curr Opin Crit Care. 2002; 8(2):101-5. DOI: 10.1097/00075198-200204000-00002. View

Longhi L, Saatman K, Fujimoto S, Raghupathi R, Meaney D, Davis J . Temporal window of vulnerability to repetitive experimental concussive brain injury. Neurosurgery. 2005; 56(2):364-74. DOI: 10.1227/01.neu.0000149008.73513.44. View

Annunziata P, Cioni C, Santonini R, Paccagnini E . Substance P antagonist blocks leakage and reduces activation of cytokine-stimulated rat brain endothelium. J Neuroimmunol. 2002; 131(1-2):41-9. DOI: 10.1016/s0165-5728(02)00262-x. View

Kimelberg H . Current concepts of brain edema. Review of laboratory investigations. J Neurosurg. 1995; 83(6):1051-9. DOI: 10.3171/jns.1995.83.6.1051. View

10.

Holzer P . Neurogenic vasodilatation and plasma leakage in the skin. Gen Pharmacol. 1998; 30(1):5-11. DOI: 10.1016/s0306-3623(97)00078-5. View

11.

Weglicki W, Phillips T, Mak I, Cassidy M, Dickens B, Stafford R . Cytokines, neuropeptides, and reperfusion injury during magnesium deficiency. Ann N Y Acad Sci. 1994; 723:246-57. View

12.

Zimmerman B, Anderson D, Granger D . Neuropeptides promote neutrophil adherence to endothelial cell monolayers. Am J Physiol. 1992; 263(5 Pt 1):G678-82. DOI: 10.1152/ajpgi.1992.263.5.G678. View

13.

van Landeghem F, Weiss T, Oehmichen M, von Deimling A . Decreased expression of glutamate transporters in astrocytes after human traumatic brain injury. J Neurotrauma. 2006; 23(10):1518-28. DOI: 10.1089/neu.2006.23.1518. View

14.

Lan J, Skeberdis V, Jover T, Grooms S, Lin Y, Araneda R . Protein kinase C modulates NMDA receptor trafficking and gating. Nat Neurosci. 2001; 4(4):382-90. DOI: 10.1038/86028. View

15.

Turner R, Vink R . Combined tissue plasminogen activator and an NK1 tachykinin receptor antagonist: an effective treatment for reperfusion injury following acute ischemic stroke in rats. Neuroscience. 2012; 220:1-10. DOI: 10.1016/j.neuroscience.2012.06.047. View

16.

Alexander S, Benson H, Faccenda E, Pawson A, Sharman J, Spedding M . The Concise Guide to PHARMACOLOGY 2013/14: ligand-gated ion channels. Br J Pharmacol. 2014; 170(8):1582-606. PMC: 3892288. DOI: 10.1111/bph.12446. View

17.

Donkin J, Nimmo A, Cernak I, Blumbergs P, Vink R . Substance P is associated with the development of brain edema and functional deficits after traumatic brain injury. J Cereb Blood Flow Metab. 2009; 29(8):1388-98. DOI: 10.1038/jcbfm.2009.63. View

18.

Regoli D, Boudon A, Fauchere J . Receptors and antagonists for substance P and related peptides. Pharmacol Rev. 1994; 46(4):551-99. View

19.

McCORMACK R, Hart R, Ganea D . Expression of NK-1 receptor mRNA in murine T lymphocytes. Neuroimmunomodulation. 1996; 3(1):35-46. DOI: 10.1159/000097225. View

20.

Vink R, Donkin J, Cruz M, Nimmo A, Cernak I . A substance P antagonist increases brain intracellular free magnesium concentration after diffuse traumatic brain injury in rats. J Am Coll Nutr. 2004; 23(5):538S-540S. DOI: 10.1080/07315724.2004.10719398. View